HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
和黄医药（纳斯达克/伦敦证交所：HCM）是一家处于商业化阶段的创新型生物医药公司，致力于发现、全球开发和商业化治疗癌症和免疫性疾病的靶向药物和免疫疗法。和黃醫藥是一家處于商業化階段的創新型生物醫藥公司，致力于發現、全球開發和商業化治療癌症和免疫性疾病的靶向藥物和免疫療法。
Location: China, Hong Kong, Hong Kong Island
Member count: 1001-5000
Total raised: $735M
Founded date: 2000
Investors 1
| Date | Name | Website |
| 16.07.2020 | General At... | generalatl... |
Funding Rounds 3
| Date | Series | Amount | Investors | Deal News |
| 13.07.2021 | - | $535M | - | - |
| 08.04.2021 | - | $100M | - | dealstreet... |
| 25.06.2020 | - | $100M | General At... | finsmes.co... |
Mentions in press and media 16
| Date | Title | Description | Category | Author | Source |
| 13.07.2021 | AstraZenec... | HONG KONG and SHANGHAI, China ... | - | - | marketscre... |
| 13.07.2021 | HUTCHMED L... | HUTCHMED (China) Limited annou... | - | - | marketscre... |
| 18.06.2021 | HUTCHMED (... | By P.R. Venkat Hutchmed (Chin... | - | - | marketscre... |
| 09.04.2021 | HK-based b... | Hong Kong-based buyout firm Ba... | - | Eudora Wan... | dealstreet... |
| 09.04.2021 | HK-based b... | Premium Hong Kong-based buyou... | - | Eudora Wan... | dealstreet... |
| 08.04.2021 | HUTCHISON ... | NOT FOR RELEASE, PUBLICATION O... | - | - | marketscre... |
| 09.12.2020 | With plans... | Hutchison China MediTech, or... | - | Conner Mit... | endpts.com... |
| 25.06.2020 | Chi-Med Re... | Hutchison China MediTech Limit... | China | - | finsmes.co... |
| 25.06.2020 | Chi-Med An... | Strategic investment demonstra... | - | - | generalatl... |
| 01.06.2020 | AbbVie g... | → AbbVie has found its next ... | - | Amber Tong | endpts.com... |
Show more